Business Context and Reporting Period
This Form 8-K, dated July 28, 2023 (reporting events through July 31, 2023), concerns TRxADE Health, Inc. (Nasdaq: MEDS). The filing primarily announces the completion of a merger with Superlatus, Inc., a U.S.-based holding company for food products and distribution, on July 31, 2023. The transaction was executed under an Amended and Restated Agreement and Plan of Merger dated July 14, 2023.
Key Financial Metrics and Transaction Terms
The filing details the consideration paid to Superlatus shareholders rather than providing standard operating financial metrics like revenue or cash flow for the period.
- Equity Issuance: Superlatus shareholders received 136,441 shares of MEDS common stock, representing 19.9% of the total issued and outstanding common stock post-merger.
- Preferred Stock Issuance: Superlatus shareholders received 306,855 shares of MEDS Series B Preferred Stock with a 100-to-1 conversion ratio.
- Stockholders' Equity: As a result of the merger, the Company's stockholders' equity exceeded the Nasdaq minimum requirement of $2,500,000.
- Liquidity and Debt: The filing text does not provide specific values for cash flow, debt levels, or liquidity ratios.
Material Changes and Corporate Actions
The most significant material change is the acquisition of Superlatus, making it a wholly-owned subsidiary of TRxADE Health, Inc. Additional corporate actions include:
- MEDS Rights: The Company issued non-transferable rights to existing shareholders (one right per share, with seven rights issued per share held) to receive one share of common stock at no cost, conditioned on executing a Registration Rights Agreement. These rights become transferable one year post-merger if no registration occurs.
- Lock-Up Agreements: Certain Superlatus shareholders and MEDS directors/officers entered into 360-day lock-up agreements restricting the sale or transfer of shares held at closing.
- Board Appointment: Candice Beaumont, Executive Director of Superlatus, was appointed to the Board of Directors effective July 31, 2023.
Outlook, Risks, and Contingencies
The filing addresses a critical regulatory contingency regarding the Company's listing status on The Nasdaq Stock Market.
- Nasdaq Compliance: The Company received an extension from the Nasdaq Hearings Panel until July 31, 2023, to demonstrate compliance with the $2,500,000 minimum stockholders' equity requirement (Rule 5550(b)(1)). The merger successfully restored compliance.
- Delisting Risk: Nasdaq will continue to monitor ongoing compliance. The filing explicitly states there can be no assurance the Company will maintain compliance with the minimum stockholders' equity requirement in future periods, which could subject the Company to delisting.
- Management Commentary: The filing incorporates a press release (Exhibit 99.1) regarding the closing but does not provide forward-looking financial guidance or revenue projections within the text of this report.
Investor Verification Checklist
- Verify the exact post-merger share count and the dilution impact of the 136,441 common shares and 306,855 Series B Preferred shares issued to Superlatus.
- Confirm the current status of the "MEDS Rights" and whether the Registration Rights Agreement has been executed by shareholders.
- Review the Company's next periodic report (10-Q or 10-K) to ensure continued compliance with the $2,500,000 Nasdaq stockholders' equity requirement.
- Examine the financial statements of Superlatus to understand the revenue and asset base added to TRxADE Health, Inc. through this acquisition.
- Check for any subsequent filings regarding the 360-day lock-up expiration dates for key insiders.